

Human CCL23/MPIF-1 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF371


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human CCL23/MPIF-1 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant human (rh) MIP-1δ, rhHCC-1, rhMIP-1α and recombinant mouse MIP-1γ is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	E. coli-derived recombinant human CCL23/MPIF-1 Arg22-Asn120 Accession # P55773		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	, , , ,		
	Recommended Concentration	Sample	
Western Blot	0.1 μg/mL	Recombinant Human CCL23/MPIF-1 (Catalog # 371-MP)	
Neutralization	Measured by its ability to neutralize CCL23/MPIF-1-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR1. The Neutralization Dose (ND ₅₀) is typically 0.5-2.5 µg/mL in the presence of		
	20 ng/mL Recombinant Human CCL23/MPIF-1 aa 46-120.		

DATA



Chemotaxis Induced by CCL23/MPIF-1 and Neutralization by Human CCL23/MPIF-1 Antibody. Recombinant Human CCL23/ MPIF-1 (Catalog # 131-M1) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR1 in a dosedependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL23/ MPIF-1 (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CCL23/MPIF-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF371). The ND₅₀ is typically 0.5-2.5 µg/mL.

PREPARATION AND STORAGE

 Reconstitution
 Reconstitute at 0.2 mg/mL in sterile PBS.

 Shipping
 The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

 *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Rev. 2/6/2018 Page 1 of 2





Human CCL23/MPIF-1 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF371

BACKGROUND

Myeloid progenitor inhibitory factor (MPIF-1), also known as CKβ8 and MIP-3, is a member of the CC chemokine subfamily that is designated CCL23. Alternative splicing of the MPIF-1 gene results in two mRNAs that encode a short (CKβ8) and a long (CKβ8-1) isoform of the chemokine. CKβ8 cDNA encodes a 120 amino acid (aa) residue precursor protein with a putative 21 aa residue signal peptide that is cleaved to generate a 99 aa residue mature CKβ8 (aa 22-120). Additional N-terminal processing of the 99 aa residue variant can generate a 75 aa residue CKβ8 (aa 46-120) that is significantly more active than the 99 aa residue variant. Similarly, CKβ8-1 encodes a 137 aa residue precursor protein that can give rise to a 116 and a 92 aa residue chemokine. Among CC chemokine members, MPIF-1 is most closely related to MIP-5/CCL15 (67% sequence identity) and MIP-1α/CCL3 (51%). MPIF-1 mRNA is most abundant in the adult lung and liver, but is also present in bone marrow, placenta, and various myelomonocytic cell lines. MPIF-1 has been shown to suppress the low proliferative potential colony-forming cells that give rise to granulocyte and monocyte lineages. MPIF-1 binds to CCR1 with high affinity and has been shown to be a potent chemoattractant and activator of monocytes, dendritic cells, and osteoclast precursors.

References:

- 1. Patel, V. et al. (1997) J. Exp. Med. 185:1163.
- 2. Youn, B-S. et al. (1998) Blood 91:3118.
- 3. Nardelli, B. et al. (1999) J. Leukoc. Biol. 61:822.
- 4. Berkhout, T.A. et al. (2000) Biochem. Pharmacol. 59:591.

Rev. 2/6/2018 Page 2 of 2

